Dapagliflozin 10 mg and Gliclazide SR 60 mg: Uses, Benefits, and Side Effects

In the fast-moving world of managing Type 2 diabetes, GLICLAGLAZE DAPA 60-10 from Steris Healthcare is a game changer. This combo pill mixes Dapagliflozin 10 mg and Gliclazide SR 60 mg for a simple, once-a-day treatment that fights high blood sugar on different fronts.

Type 2 Diabetes Mellitus affects more than 100 million people just in India, showing how huge the need for good management is. Juggling this disease means using several strategies, and GLICLAGLAZE DAPA 60-10 fits right into that plan. It’s super precise and makes it easier for folks to stick with their treatments.

If you’re a doctor, a pharmacist, or a patient looking up info on this duo of drugs, this guide is your go-to spot. We cover everything you need to know in one handy, accurate place.

 

Composition & Pharmacological Profile of GLICLAGLAZE DAPA 60-10

GLICLAGLAZE DAPA 60-10 is a precisely formulated tablet combining two pharmacologically distinct agents working synergistically to control blood glucose:

 

Parameter	Dapagliflozin (Component 1)	Gliclazide SR (Component 2)
Drug Class	SGLT2 Inhibitor (Gliflozin)	Sulphonylurea (2nd Generation)
Dose per Tablet	10 mg	60 mg (Sustained Release)
Primary Mechanism	Blocks renal glucose reabsorption → glycosuria	Stimulates pancreatic beta-cell insulin secretion
Site of Action	Kidney (proximal tubule)	Pancreatic Beta Cells
Glucose-Dependent?	No (works independently of insulin)	Yes (requires functioning beta cells)
Additional Benefits	Cardioprotective, nephroprotective, weight loss	Low hypoglycaemia risk vs older sulphonylureas
Half-Life	~12.9 hours	~16 hours (SR formulation)

 

 

How Does GLICLAGLAZE DAPA 60-10 Work? Mechanism of Action Explained

Understanding how dapagliflozin 10 gliclazide 60 works requires looking at both components independently, then appreciating their combined synergy:

Dapagliflozin 10 mg – SGLT2 Inhibitor Mechanism

Dapagliflozin is a selective inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2), a protein located in the S1 segment of the proximal renal tubule. Under normal physiology, SGLT2 reabsorbs approximately 90% of filtered glucose back into the bloodstream.

When Dapagliflozin blocks SGLT2, the body is unable to reabsorb this glucose, leading to its excretion via urine — a process called glucosuria. This insulin-independent mechanism lowers blood glucose irrespective of beta-cell function, making it uniquely valuable in patients with diminished pancreatic reserve.

Key outcomes of Dapagliflozin action:

• Urinary glucose excretion of ~70g/day (approximately 280 kcal)

• HbA1c reduction of 0.5–1.2%

• Weight reduction of 2–3 kg over 24 weeks

• Systolic blood pressure reduction of 3–5 mmHg

• Cardioprotective and nephroprotective effects (DECLARE-TIMI 58 trial)

 

Gliclazide SR 60 mg – Sulphonylurea Mechanism

Gliclazide belongs to the second-generation sulphonylurea class. It acts by binding to specific SUR1 receptors on pancreatic beta-cell membranes, inhibiting ATP-sensitive potassium channels (KATP). This membrane depolarisation triggers calcium influx and subsequent insulin secretion.

The SR (Sustained Release) formulation ensures gradual, prolonged drug release over 24 hours, providing consistent insulin secretagogue activity while reducing peak-related hypoglycaemia risk. Gliclazide SR is also associated with antioxidant and antithrombotic properties — a clinical advantage not seen with earlier sulphonylureas.

Key outcomes of Gliclazide SR action:

• HbA1c reduction of 1.0–1.5%

• Stimulates both first and second phase insulin release

• Reduces platelet aggregation (antithrombotic benefit)

• Free radical scavenging activity (antioxidant)

• Lower hypoglycaemia risk vs glibenclamide

 

Synergistic Dual-Action: Why the Combination Works

The combination of dapagliflozin 10 mg and gliclazide SR 60 mg addresses T2DM through two entirely distinct pathways — one insulin-independent (renal glucose excretion) and one insulin-dependent (pancreatic stimulation). This complementarity means:

• Greater HbA1c reduction (1.5–2.5%) than either drug alone

• Weight neutrality or mild weight loss (SGLT2 offset reduces sulphonylurea weight gain)

• Reduced risk of hypoglycaemia compared to older SU combinations

• Cardiovascular and renal protective overlay from dapagliflozin

 

Can Gliclazide and Dapagliflozin Be Taken Together?

Yes — gliclazide and dapagliflozin can be taken together and this combination is not only clinically safe but also increasingly recommended in modern T2DM management guidelines, including ADA (American Diabetes Association) and IDF (International Diabetes Federation) protocols.

Several landmark clinical studies and real-world evidence support the co-administration of SGLT2 inhibitors with sulphonylureas:

• The complementary mechanisms avoid pharmacokinetic interactions

• Both drugs are renally cleared but at different tubular sites — no competition exists

• No clinically significant drug-drug interaction has been identified between dapagliflozin and gliclazide

• The combination is approved and marketed as fixed-dose formulations in multiple countries including India

Important clinical consideration: When combining any sulphonylurea with an SGLT2 inhibitor, the prescribing physician may consider a dose reduction of gliclazide in patients with pre-existing hypoglycaemia risk. This is a precautionary step, not a contraindication to combined use.

GLICLAGLAZE DAPA 60-10 by Steris Healthcare is specifically formulated to deliver this combination in a single convenient tablet, eliminating polypharmacy burden and improving medication adherence.

 

Which is Better — Gliclazide or Dapagliflozin?

This is one of the most commonly searched clinical questions, and the answer depends on the patient's individual profile. Here's a comprehensive evidence-based comparison:

 

Comparison Parameter	Gliclazide SR 60 mg	Dapagliflozin 10 mg
Drug Class	Sulphonylurea	SGLT2 Inhibitor
HbA1c Reduction	1.0–1.5%	0.5–1.2%
Mechanism	Insulin secretagogue	Renal glucose excretion
Weight Effect	Neutral to mild weight gain	Weight loss (2–3 kg)
Hypoglycaemia Risk	Low to moderate	Very low (insulin-independent)
Cardiovascular Benefit	Neutral	Proven (DECLARE-TIMI 58)
Renal Benefit	Neutral	Proven (DAPA-CKD trial)
Cost Profile	Lower	Higher (but combination = value)
Use in CKD	Caution below eGFR 45	Reduced efficacy below eGFR 45
Requirement	Functional beta cells needed	Works without beta cells

 

Clinical Answer: Neither drug is universally 'better' — they serve different patient profiles. Gliclazide SR offers superior HbA1c lowering in patients with residual beta-cell function; dapagliflozin adds cardiometabolic and nephroprotective benefits. When used together in GLICLAGLAZE DAPA 60-10, patients receive the best of both mechanisms — making the combination therapeutically superior to either monotherapy in most T2DM cases requiring dual-agent therapy.

 

What is GLICLAGLAZE DAPA 60-10 Used For? Indications & Clinical Uses

Primary Indication

GLICLAGLAZE DAPA 60-10 (Dapagliflozin 10 mg + Gliclazide SR 60 mg) is indicated for:

• Treatment of Type 2 Diabetes Mellitus (T2DM) in adults aged 18 and above

• As an adjunct to diet and exercise in patients where monotherapy with metformin, gliclazide alone, or dapagliflozin alone has provided insufficient glycaemic control

• As a step-up from dual oral therapy (e.g., metformin + one OHA) when triple therapy is required

• In patients who require both insulin secretagogue and SGLT2 inhibitor effects

 

What is Gliclazide SR 60 mg Used For?

Gliclazide SR 60 mg, as a standalone agent or in combination, is specifically used for:

• Lowering fasting and postprandial blood glucose in T2DM

• Reducing HbA1c to target levels (typically <7.0%)

• Managing T2DM in patients with good renal function (eGFR > 45 mL/min)

• Patients who respond well to insulin secretagogue therapy

• Patients at risk for oxidative stress-related diabetic complications due to its antioxidant properties

 

What is Dapagliflozin 10 Gliclazide 60 Combination Used For?

The fixed-dose combination specifically targets patients who need:

• Dual-mechanism glycaemic control in a single tablet

• HbA1c reduction beyond what one drug can achieve

• Added cardiovascular protection (dapagliflozin's heart failure and MACE benefits)

• Renal protection (dapagliflozin reduces progression of diabetic nephropathy)

• Weight management as part of T2DM therapy

• Simplified once-daily dosing to improve compliance

 

Benefits of GLICLAGLAZE DAPA 60-10 – Why Choose This Combination?

GLICLAGLAZE DAPA 60-10 from Steris Healthcare offers a clinically robust set of benefits that extend well beyond simple blood sugar control:

1. Superior Glycaemic Efficacy

The dual mechanism delivers HbA1c reduction of up to 2.5%, which is significantly greater than either gliclazide or dapagliflozin monotherapy. Patients typically achieve HbA1c targets of <7.0% within 12–24 weeks of initiating therapy.

2. Cardiovascular Protection

Dapagliflozin's inclusion in this FDC brings proven cardiovascular benefits. The DECLARE-TIMI 58 trial demonstrated significant reduction in hospitalization for heart failure and major adverse cardiovascular events (MACE) in T2DM patients — benefits that extend to the GLICLAGLAZE DAPA 60-10 combination.

3. Renal Protection

The DAPA-CKD trial confirmed dapagliflozin slows the progression of chronic kidney disease in diabetic patients. GLICLAGLAZE DAPA 60-10 thus provides organ-protective benefits that pure secretagogue therapy cannot.

4. Weight Management

Dapagliflozin causes caloric loss through urinary glucose excretion (~280 kcal/day), counteracting the mild weight gain sometimes seen with sulphonylureas. The combination is typically weight-neutral to mildly weight-reducing — a significant advantage in the obese T2DM patient.

5. Blood Pressure Reduction

Dapagliflozin provides modest systolic blood pressure reduction (3–5 mmHg) through osmotic diuresis — beneficial in hypertensive diabetic patients, reducing polypharmacy needs.

6. Reduced Hypoglycaemia Risk

Gliclazide SR's once-daily sustained-release formulation reduces peak plasma concentrations, minimising hypoglycaemia risk. Combined with dapagliflozin's insulin-independent mechanism, the overall hypoglycaemia burden of GLICLAGLAZE DAPA 60-10 is lower than older SU-based combinations.

7. Single Tablet Convenience

One tablet, once daily. GLICLAGLAZE DAPA 60-10 eliminates the need to manage two separate prescriptions, reducing pill burden, improving adherence, and simplifying diabetes management for both patients and caregivers.

8. Antioxidant and Antithrombotic Properties

Gliclazide's unique free-radical scavenging and antiplatelet aggregation properties offer micro and macrovascular protection — reducing the long-term diabetic complication burden.

 

Dosage, Administration & How to Take GLICLAGLAZE DAPA 60-10

Recommended Dosage

 

Patient Type	Recommended Dose	Timing	Special Notes
Standard T2DM Adult	1 tablet (Dapa 10mg + Gli SR 60mg) once daily	With breakfast / first meal	Swallow whole — do not crush/split SR tablet
Elderly (>65 years)	Start at lower dose; monitor renal function	With breakfast	Monitor eGFR before initiating
Mild to Moderate CKD (eGFR 45–60)	Use with caution; physician assessment required	With meal	Reduced dapagliflozin efficacy below eGFR 45
Severe Renal Impairment (eGFR <30)	Contraindicated	—	Both components have renal clearance issues
Hepatic Impairment	Use with caution (severe impairment: avoid)	With meal	Monitor liver enzymes periodically

 

Important Dosage Instructions

• Always take GLICLAGLAZE DAPA 60-10 with breakfast or the first main meal of the day

• Do NOT crush, chew, or split the tablet — the SR matrix must remain intact for proper release

• If a dose is missed, take it as soon as remembered. If it is near the time for the next dose, skip the missed dose. Do NOT double up

• Maintain adequate hydration during therapy (dapagliflozin increases urine output)

• Regular HbA1c monitoring every 3 months is recommended for the first year

 

When to Seek Medical Attention During GLICLAGLAZE DAPA 60-10 Therapy

• Symptoms of hypoglycaemia: trembling, sweating, confusion, palpitations

• Genital itching or unusual vaginal/penile discharge (UTI or genital mycotic infection)

• Painful or reduced urination (urinary tract infection)

• Unusual fatigue, nausea, abdominal pain (rare: Diabetic Ketoacidosis — seek emergency care)

• Swelling of ankles or feet

 

Side Effects & Safety Profile of Dapagliflozin 10 mg and Gliclazide SR 60 mg

GLICLAGLAZE DAPA 60-10 is generally well-tolerated. However, as with all medications, certain adverse effects may occur:

 

Side Effect	Component Responsible	Frequency	Management
Genital mycotic infections (thrush)	Dapagliflozin (glycosuria)	Common (~5%)	Antifungal treatment; hygiene advice
UTI (urinary tract infection)	Dapagliflozin	Common (~4%)	Antibiotics; increased hydration
Hypoglycaemia	Gliclazide SR	Uncommon (~2%)	Glucose correction; dose review
Increased urination (polyuria)	Dapagliflozin	Common	Reassure; ensure hydration
Nausea / GI upset	Both (mild)	Uncommon	Take with food
DKA (Diabetic Ketoacidosis)	Dapagliflozin (rare)	Very rare	Emergency care; stop drug
Weight loss	Dapagliflozin	Common (beneficial)	Monitor BMI
Mild hypotension / dizziness	Dapagliflozin (diuresis)	Uncommon	Hydration; BP monitoring

 

Note: This is not an exhaustive list. Always refer to the prescribing information and consult your physician or pharmacist for complete safety guidance.

 

Contraindications & Precautions

GLICLAGLAZE DAPA 60-10 should NOT be used in:

• Type 1 Diabetes Mellitus (absolute contraindication)

• Severe renal impairment (eGFR < 30 mL/min/1.73m²)

• Active urinary tract infection

• Pregnancy and breastfeeding

• Known hypersensitivity to dapagliflozin, gliclazide, or any sulphonylurea

• Patients at high DKA risk (prolonged fasting, major surgery, severe illness)

• Severe hepatic impairment

 

Can You Give Dapagliflozin with Gliclazide? Medical Perspective

Yes, dapagliflozin with gliclazide is a well-established, evidence-backed combination in T2DM therapy. Multiple Phase III clinical trials and post-marketing studies have confirmed:

• No pharmacokinetic interference between the two drugs

• Additive glucose-lowering effect (complementary mechanisms)

• Manageable safety profile with appropriate patient selection and monitoring

• Improved glycaemic durability compared to either agent alone

Several national and international diabetes guidelines now advocate SGLT2 inhibitor + sulphonylurea combination as an accepted dual therapy option, especially in patients with cardiovascular risk factors or those who have failed metformin monotherapy.

Steris Healthcare's GLICLAGLAZE DAPA 60-10 makes this clinically validated combination accessible in a convenient, single fixed-dose tablet, manufactured under GMP-compliant quality standards.

 

GLICLAGLAZE DAPA 60-10 Price, Availability & How to Order

Price Overview

GLICLAGLAZE DAPA 60-10 by Steris Healthcare is competitively priced to ensure wider patient access to this advanced antidiabetic combination therapy. As a fixed-dose combination, it offers significant cost savings compared to purchasing dapagliflozin and gliclazide SR as separate prescriptions.

For current pricing, trade enquiries, and stock availability, contact Steris Healthcare directly.

The fixed-dose combination format means:

• Lower per-unit cost than purchasing two separate branded drugs

• Reduced pharmacy dispensing fees (single prescription)

• Insurance/formulary coverage may apply under antidiabetic combination category

• Available through authorised pharmaceutical distributors and stockists across India

 

How to Obtain GLICLAGLAZE DAPA 60-10

• Prescription-only medication — requires valid physician prescription

• Available at licensed pharmacy outlets with valid trade licence

• Enquire at: Steris Healthcare — authorised trade and distribution network

• Medical representatives (MRs) can provide samples and literature to healthcare professionals

 

About Steris Healthcare – Manufacturer of GLICLAGLAZE DAPA 60-10

Steris Healthcare is a committed Indian pharmaceutical company dedicated to developing high-quality, evidence-based medicines that address the growing burden of chronic diseases, including diabetes, cardiovascular conditions, and metabolic disorders.

Steris Healthcare's product philosophy is built on:

• Science-driven formulation development using clinically validated active pharmaceutical ingredients

• GMP-compliant manufacturing processes meeting national and international standards

• Accessible pricing to ensure equitable reach across patient populations

• Robust medical education and healthcare professional support programmes

• Patient-centric combination therapy design to improve adherence and outcomes

GLICLAGLAZE DAPA 60-10 exemplifies Steris Healthcare's commitment to innovation in diabetes management — combining two globally proven molecules in a single, convenient formulation that simplifies treatment without compromising clinical efficacy.

 

Conclusion – GLICLAGLAZE DAPA 60-10 by Steris Healthcare

GLICLAGLAZE DAPA 60-10 — combining Dapagliflozin 10 mg and Gliclazide SR 60 mg — represents a meaningful advancement in fixed-dose combination diabetes therapy from Steris Healthcare. It addresses the well-documented need for multi-mechanism oral antidiabetic therapy in India's large and growing Type 2 diabetes population.

By harnessing the complementary actions of SGLT2 inhibition and sulphonylurea-mediated insulin secretion, GLICLAGLAZE DAPA 60-10 delivers:

• Superior HbA1c reduction compared to monotherapy

• Cardiovascular and renal organ protection

• Improved weight outcomes

• Reduced pill burden for better patient adherence

• A clinically rational, guideline-aligned treatment approach

For healthcare professionals evaluating advanced antidiabetic combinations, GLICLAGLAZE DAPA 60-10 by Steris Healthcare offers a compelling clinical case backed by robust evidence on its constituent molecules. For patients requiring step-up dual therapy, it represents a simpler, smarter way to manage Type 2 diabetes.

Consult your physician or healthcare provider before initiating, modifying, or discontinuing any antidiabetic therapy. This article is intended for informational and educational purposes only and does not constitute medical advice.

 

 

Frequently Asked Questions for GLICLAGLAZE DAPA 60-10

Is dapagliflozin 10 mg and gliclazide SR 60 mg safe for elderly patients?

GLICLAGLAZE DAPA 60-10 can be used in elderly T2DM patients (>65 years) with appropriate precautions. Physicians should assess renal function (eGFR), risk of dehydration, and hypoglycaemia risk before prescribing. Lower initial doses or careful titration may be recommended.

What is the difference between gliclazide SR 60 mg MR and regular gliclazide?

Gliclazide SR (Sustained Release) or MR (Modified Release) at 60 mg delivers drug in a controlled manner over 24 hours. This results in smoother plasma levels, better postprandial glucose control, reduced hypoglycaemia risk, and once-daily dosing convenience compared to conventional gliclazide 80 mg tablets (twice daily).

How long does it take for GLICLAGLAZE DAPA 60-10 to lower blood sugar?

Dapagliflozin begins lowering blood glucose within 1–2 hours of the first dose by initiating glucosuria. Gliclazide SR typically shows peak insulin-stimulating effect 2–4 hours post-dose. Meaningful HbA1c reduction is typically observed at 8–12 weeks, with maximum efficacy established by 24 weeks.

Can GLICLAGLAZE DAPA 60-10 be used with metformin?

Yes — GLICLAGLAZE DAPA 60-10 can be combined with metformin in patients requiring triple oral antidiabetic therapy. Metformin + dapagliflozin + gliclazide SR is a clinically rational triple combination addressing insulin resistance (metformin), glucose excretion (dapagliflozin), and secretagogue (gliclazide) pathways simultaneously.

Does dapagliflozin cause weight loss in combination with gliclazide?

Yes. Dapagliflozin's urinary glucose excretion (~280 kcal/day) promotes weight loss of 2–3 kg over 24 weeks. In the combination tablet, this helps offset the mild weight gain sometimes associated with sulphonylureas, resulting in net weight neutrality or modest weight loss — a clinically valuable outcome for overweight T2DM patients.

What is the HbA1c reduction expected from GLICLAGLAZE DAPA 60-10?

Clinical data suggests the dapagliflozin 10mg gliclazide 60mg combination can reduce HbA1c by 1.5–2.5% from baseline, depending on the patient's starting HbA1c. Patients with higher baseline HbA1c (>9%) tend to show greater absolute reduction.

Is GLICLAGLAZE DAPA 60-10 suitable for patients with heart disease?

Dapagliflozin has a proven cardiovascular safety profile and demonstrated heart failure hospitalisation reduction. GLICLAGLAZE DAPA 60-10 may be particularly beneficial for T2DM patients with established cardiovascular disease or at high cardiovascular risk, subject to physician assessment and eGFR criteria.

 

Medical Disclaimer

This content is produced by Steris Healthcare for informational and educational purposes related to GLICLAGLAZE DAPA 60-10. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional before starting or modifying medication. Prescribing information is subject to regulatory approval and regional guidelines.

© 2026 Steris Healthcare | GLICLAGLAZE DAPA 60-10 | Dapagliflozin 10 mg + Gliclazide SR 60 mg